News &amp; Updates

The interleukin (IL) 6 proinflammatory trans-signaling inhibitor olamkicept appears safe and effective in the treatment of patients with inflammatory bowel disease (IBD), according to the results of the phase IIa FUTURE trial.

IL6 trans-signaling blockade holds therapeutic promise in IBD

Bevacizumab for ROP does not heighten risk of severe neurodevelopment impairment in infants

Patients with retinopathy of prematurity (ROP) who received intravitreal bevacizumab (IVB) therapy are not at an increased risk of severe neurodevelopmental impairment (sNDI), a study has shown.

Bevacizumab for ROP does not heighten risk of severe neurodevelopment impairment in infants

Exercise + liraglutide maintains healthy weight loss in obese people

04 Jun 2021 by

Combining exercise and liraglutide treatment is more effective in improving and maintaining healthy weight loss than either strategy alone in people with obesity, reveals a head-to-head study.

Exercise + liraglutide maintains healthy weight loss in obese people

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

A 6-month course of nivolumab and low-dose ipilimumab appears to be a potential adjuvant treatment for patients with resected melanoma, suggests a study, indicating further research on this regimen.

Short-course nivolumab-ipilimumab shows promise as adjuvant treatment for melanoma

Long-term study findings reflect potential of sotatercept for PAH

04 Jun 2021 by

The efficacy and safety of the novel, first-in-class, selective fusion protein sotatercept were sustained or enhanced for up to 48 weeks when added to standard of care (SOC) for the treatment of pulmonary arterial hypertension (PAH), according to interim findings of the ongoing open-label extension (OLE) period of the phase II PULSAR trial presented at ATS 2021.

Long-term study findings reflect potential of sotatercept for PAH

M89 regimen improves skin conditions of rosacea

04 Jun 2021 by

Daily application of M89, which contains 89% Vichy volcanic mineralizing water (VVMW) and 0.4% hyaluronic acid, significantly improves skin characteristics in individuals with clinical signs and symptoms of rosacea, according to a study presented at AAD 2021.

M89 regimen improves skin conditions of rosacea

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

Long-term use of peginterferon therapy appears to induce sustained virologic response in about half of patients with hepatitis D virus infection, along with functional cure in some patients, as reported in a study.

Extended peginterferon therapy yields durable virologic suppression in hepatitis D

Mirogabalin expands treatment option for Asians with peripheral neuropathic pain

03 Jun 2021 by

Mirogabalin besylate appears to provide an early analgesic effect in Asian patients with peripheral neuropathic pain (PNP) with a tolerable safety profile, according to a pooled analysis of two phase III studies.

Mirogabalin expands treatment option for Asians with peripheral neuropathic pain

Diabetes drug shows CV benefit for patients with diabetes, HF

03 Jun 2021 by

The sodium glucose cotransporter 1/2 inhibitor sotagliflozin reduced the primary composite endpoint of cardiovascular (CV) deaths, hospitalizations for heart failure (HF), and urgent visits for HF in patients with type 2 diabetes and HF, including those with HF with preserved ejection fraction (HFpEF; EF ≥50 percent), according to the pooled analysis of the SOLOIST* and SCORED** trials presented at ACC.21.

Diabetes drug shows CV benefit for patients with diabetes, HF

Antibiotics reduce efficacy of immune checkpoint inhibitors

Use of antibiotics during immune checkpoint blockade (ICB) has a significantly negative impact on the efficacy of immunotherapy, reveals a study. The greatest negative impact occurs when using antibiotics in the first 6 weeks after initiating ICB.

Antibiotics reduce efficacy of immune checkpoint inhibitors